CD274 and small cell lung carcinoma: FDA has approved PD-1 inhibitors as third-line treatment in 2018 and PD-L1 inhibitors as first-line treatment in 2020 for patients with ED or relapsed SCLC, which is an important advancement for SCLC patients.